Heparin-induced thrombocytopaenia complicated by arterial and venous thrombosis: report of 2 cases successfully treated by a danaparoid sodium.
Heparin-induced thrombocytopaenia is a dreaded, although infrequent, complication of heparin therapy. We report two cases of heparin-induced thrombocytopaenia (HIT) type II occurring in a patient treated with standard (unfractionated) heparin and in another patient given a low-weight molecular heparin. The clinical course of the first patient illustrates the potentially severe thrombotic complications of HIT. Both cases were treated successfully by danaparoid sodium. Clues to the diagnosis and treatment are briefly discussed.
Darling
K
K
General Internal Medicine Unit, Cliniques Universitaires St Luc, Bruxelles, Belgium.
Jaumotte
C
C
Saussoy
P
P
Zech
F
F
Lavenne
E
E
Hainaut
P
P
D000925:Anticoagulants / Q000009:adverse effects*; D000990:Antithrombin III / Q000627:therapeutic use*; D002809:Chondroitin Sulfates / Q000627:therapeutic use*; D003871:Dermatan Sulfate / Q000627:therapeutic use*; D004338:Drug Combinations; D005260:Female; D006493:Heparin / Q000009:adverse effects*; D006495:Heparin, Low-Molecular-Weight / Q000009:adverse effects; D006496:Heparinoids / Q000627:therapeutic use*; D006497:Heparan Sulfate / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D013921:Thrombocytopenia / Q000139:chemically induced* / Q000188:drug therapy; D013927:Thrombosis / Q000139:chemically induced* / Q000188:drug therapy; D020246:Venous Thrombosis / Q000139:chemically induced* / Q000188:drug therapy
D000925:Anticoagulants; D000990:Antithrombin III; D002809:Chondroitin Sulfates; D003871:Dermatan Sulfate; D004338:Drug Combinations; D006493:Heparin; D006495:Heparin, Low-Molecular-Weight; D006496:Heparinoids; D006497:Heparan Sulfate; C035838:danaparoid